Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP355
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**STP355** is a Sirnaomics investigational dual-siRNA nanoparticle therapy for solid tumors, including breast cancer, melanoma, and colorectal cancer. It co-formulates siRNAs designed to silence **transforming growth factor beta-1** and **vascular endothelial growth factor receptor 2** expression in a proprietary polypeptide nanoparticle delivery platform, with the goal of simultaneously reducing immunosuppressive tumor-microenvironment signaling and tumor angiogenesis. Preclinical melanoma studies reported intravenous administration, dual-target knockdown, reduced tumor growth and lung metastasis, and increased immune-cell penetration into tumors. ([sirnaomics.com](https://sirnaomics.com/en/science-pipeline/pipeline/oncology/stp355))
- Other names
- STP 355STP355STP-355
02
Targets
Vascular endothelial growth factor receptor 2 (VEGFR2) messenger RNATGFB1 (Transforming growth factor Beta-1 proprotein)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on STP355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP355.